| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Melanoma | 118 | 2023 | 5591 | 8.830 |
Why?
|
| Proto-Oncogene Proteins B-raf | 39 | 2022 | 1331 | 4.340 |
Why?
|
| Skin Neoplasms | 46 | 2022 | 4888 | 3.390 |
Why?
|
| Brain Neoplasms | 21 | 2023 | 4993 | 1.860 |
Why?
|
| Oximes | 7 | 2018 | 192 | 1.510 |
Why?
|
| PTEN Phosphohydrolase | 16 | 2023 | 1014 | 1.460 |
Why?
|
| Mutation | 55 | 2021 | 15913 | 1.450 |
Why?
|
| Immunotherapy | 20 | 2023 | 3539 | 1.390 |
Why?
|
| Phosphatidylinositol 3-Kinases | 13 | 2016 | 1719 | 1.270 |
Why?
|
| Molecular Targeted Therapy | 11 | 2022 | 2398 | 1.200 |
Why?
|
| Imidazoles | 7 | 2018 | 1055 | 1.080 |
Why?
|
| Proto-Oncogene Proteins c-akt | 14 | 2015 | 2085 | 1.080 |
Why?
|
| Genes, ras | 4 | 2013 | 681 | 1.070 |
Why?
|
| Antineoplastic Agents | 22 | 2020 | 14653 | 0.900 |
Why?
|
| Pyrimidinones | 5 | 2018 | 317 | 0.820 |
Why?
|
| GTP Phosphohydrolases | 6 | 2018 | 341 | 0.800 |
Why?
|
| Drug Resistance, Neoplasm | 16 | 2020 | 5420 | 0.800 |
Why?
|
| Pyridones | 5 | 2018 | 361 | 0.790 |
Why?
|
| Mitogen-Activated Protein Kinases | 4 | 2016 | 682 | 0.790 |
Why?
|
| Proto-Oncogene Proteins c-kit | 5 | 2014 | 490 | 0.780 |
Why?
|
| Protein Kinase Inhibitors | 15 | 2022 | 4963 | 0.760 |
Why?
|
| Benzimidazoles | 4 | 2019 | 442 | 0.740 |
Why?
|
| Humans | 158 | 2023 | 271636 | 0.730 |
Why?
|
| Signal Transduction | 25 | 2018 | 12219 | 0.730 |
Why?
|
| L-Lactate Dehydrogenase | 2 | 2021 | 316 | 0.710 |
Why?
|
| Neoplasms, Second Primary | 5 | 2023 | 1387 | 0.690 |
Why?
|
| Lymphocytes, Tumor-Infiltrating | 9 | 2022 | 1013 | 0.630 |
Why?
|
| Neoplasm Metastasis | 12 | 2020 | 5328 | 0.610 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 18 | 2023 | 16606 | 0.580 |
Why?
|
| Biomarkers, Tumor | 16 | 2020 | 10743 | 0.580 |
Why?
|
| Proteomics | 6 | 2023 | 1436 | 0.560 |
Why?
|
| Neoplasms | 20 | 2022 | 15903 | 0.560 |
Why?
|
| Body Mass Index | 4 | 2023 | 2254 | 0.550 |
Why?
|
| Indoles | 6 | 2015 | 1034 | 0.550 |
Why?
|
| Oxidative Phosphorylation | 4 | 2020 | 267 | 0.540 |
Why?
|
| Phosphoric Monoester Hydrolases | 4 | 2002 | 265 | 0.530 |
Why?
|
| MAP Kinase Signaling System | 5 | 2016 | 889 | 0.520 |
Why?
|
| Point Mutation | 3 | 2013 | 794 | 0.520 |
Why?
|
| Azetidines | 1 | 2015 | 88 | 0.510 |
Why?
|
| Programmed Cell Death 1 Receptor | 8 | 2021 | 1089 | 0.510 |
Why?
|
| High-Throughput Nucleotide Sequencing | 7 | 2016 | 2349 | 0.500 |
Why?
|
| Antineoplastic Agents, Immunological | 4 | 2019 | 1335 | 0.490 |
Why?
|
| Interleukin-2 | 4 | 2014 | 890 | 0.490 |
Why?
|
| Central Nervous System Neoplasms | 2 | 2020 | 550 | 0.490 |
Why?
|
| Cell Line, Tumor | 29 | 2021 | 14868 | 0.480 |
Why?
|
| Tumor Suppressor Proteins | 6 | 2016 | 1892 | 0.470 |
Why?
|
| Ipilimumab | 7 | 2023 | 759 | 0.460 |
Why?
|
| CTLA-4 Antigen | 7 | 2021 | 681 | 0.460 |
Why?
|
| Piperidines | 2 | 2019 | 1090 | 0.460 |
Why?
|
| Sulfonamides | 7 | 2019 | 1918 | 0.450 |
Why?
|
| Membrane Proteins | 6 | 2018 | 2973 | 0.440 |
Why?
|
| Tumor Microenvironment | 7 | 2022 | 2999 | 0.420 |
Why?
|
| Multiprotein Complexes | 1 | 2014 | 388 | 0.410 |
Why?
|
| Intracranial Hemorrhages | 1 | 2012 | 119 | 0.390 |
Why?
|
| DNA Mutational Analysis | 8 | 2016 | 2365 | 0.380 |
Why?
|
| Apoptosis | 12 | 2014 | 7834 | 0.380 |
Why?
|
| Neoplasm Staging | 19 | 2022 | 13989 | 0.380 |
Why?
|
| TOR Serine-Threonine Kinases | 2 | 2014 | 1574 | 0.370 |
Why?
|
| Heterocyclic Compounds, 3-Ring | 1 | 2011 | 152 | 0.360 |
Why?
|
| Middle Aged | 47 | 2023 | 90349 | 0.360 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p21 | 1 | 2012 | 541 | 0.360 |
Why?
|
| Protein Array Analysis | 7 | 2021 | 505 | 0.350 |
Why?
|
| Melanoma, Experimental | 4 | 2021 | 385 | 0.350 |
Why?
|
| Gene Expression Regulation, Neoplastic | 15 | 2021 | 9093 | 0.340 |
Why?
|
| Benzamides | 2 | 2012 | 1882 | 0.340 |
Why?
|
| Molecular Diagnostic Techniques | 1 | 2012 | 335 | 0.330 |
Why?
|
| Male | 53 | 2023 | 128836 | 0.330 |
Why?
|
| Gastrointestinal Microbiome | 3 | 2023 | 967 | 0.330 |
Why?
|
| Female | 57 | 2022 | 148992 | 0.320 |
Why?
|
| DNA Copy Number Variations | 7 | 2023 | 1555 | 0.320 |
Why?
|
| Thiazoles | 2 | 2011 | 725 | 0.320 |
Why?
|
| Ubiquitin-Protein Ligases | 2 | 2016 | 882 | 0.320 |
Why?
|
| Prognosis | 15 | 2023 | 22525 | 0.310 |
Why?
|
| T-Lymphocytes | 8 | 2021 | 3934 | 0.310 |
Why?
|
| Clinical Trials as Topic | 7 | 2021 | 3852 | 0.300 |
Why?
|
| Drug Screening Assays, Antitumor | 1 | 2010 | 569 | 0.300 |
Why?
|
| Mitogen-Activated Protein Kinase Kinases | 3 | 2022 | 384 | 0.300 |
Why?
|
| Aged, 80 and over | 21 | 2021 | 31032 | 0.300 |
Why?
|
| Immunotherapy, Adoptive | 7 | 2022 | 1838 | 0.300 |
Why?
|
| Animals | 31 | 2022 | 62757 | 0.290 |
Why?
|
| Adult | 34 | 2021 | 81791 | 0.290 |
Why?
|
| Venous Thromboembolism | 1 | 2012 | 376 | 0.290 |
Why?
|
| Obesity | 3 | 2023 | 2952 | 0.290 |
Why?
|
| Aged | 31 | 2021 | 73421 | 0.290 |
Why?
|
| Neoplasm Proteins | 2 | 2017 | 3363 | 0.280 |
Why?
|
| Sentinel Lymph Node | 2 | 2021 | 229 | 0.280 |
Why?
|
| Anticoagulants | 1 | 2012 | 789 | 0.270 |
Why?
|
| Genomics | 5 | 2022 | 2830 | 0.260 |
Why?
|
| Cancer Vaccines | 2 | 2021 | 751 | 0.250 |
Why?
|
| Leukemia | 1 | 2014 | 1721 | 0.250 |
Why?
|
| Young Adult | 11 | 2021 | 22094 | 0.250 |
Why?
|
| Meningeal Neoplasms | 2 | 2020 | 473 | 0.250 |
Why?
|
| Neoplasm Invasiveness | 2 | 2018 | 4070 | 0.240 |
Why?
|
| Disease-Free Survival | 12 | 2022 | 10259 | 0.240 |
Why?
|
| Genes, Tumor Suppressor | 4 | 2023 | 1120 | 0.240 |
Why?
|
| Class I Phosphatidylinositol 3-Kinases | 5 | 2018 | 531 | 0.230 |
Why?
|
| Risk Assessment | 5 | 2020 | 6876 | 0.230 |
Why?
|
| Neoadjuvant Therapy | 4 | 2022 | 5209 | 0.220 |
Why?
|
| Nitric Oxide Synthase Type II | 3 | 2016 | 255 | 0.220 |
Why?
|
| Immunohistochemistry | 8 | 2020 | 7817 | 0.220 |
Why?
|
| Lymphatic Metastasis | 4 | 2020 | 4967 | 0.220 |
Why?
|
| Survival Analysis | 8 | 2022 | 9323 | 0.210 |
Why?
|
| Transfection | 3 | 2010 | 3165 | 0.210 |
Why?
|
| Cohort Studies | 8 | 2021 | 9467 | 0.210 |
Why?
|
| Drug Delivery Systems | 1 | 2006 | 662 | 0.210 |
Why?
|
| Protein Kinases | 1 | 2006 | 919 | 0.200 |
Why?
|
| Cell Proliferation | 12 | 2020 | 7292 | 0.200 |
Why?
|
| Phenylurea Compounds | 3 | 2015 | 600 | 0.190 |
Why?
|
| Androgen Receptor Antagonists | 1 | 2022 | 109 | 0.190 |
Why?
|
| Antibodies, Monoclonal | 5 | 2022 | 4495 | 0.190 |
Why?
|
| Tumor Cells, Cultured | 9 | 2019 | 5804 | 0.190 |
Why?
|
| Cell Survival | 8 | 2021 | 3075 | 0.190 |
Why?
|
| Dietary Fiber | 1 | 2021 | 126 | 0.190 |
Why?
|
| Mice | 22 | 2022 | 36006 | 0.190 |
Why?
|
| Arthritis | 1 | 2022 | 148 | 0.190 |
Why?
|
| Jaw Diseases | 1 | 2020 | 20 | 0.180 |
Why?
|
| Risk Factors | 7 | 2023 | 18016 | 0.180 |
Why?
|
| Lung Neoplasms | 5 | 2023 | 12008 | 0.180 |
Why?
|
| DNA Fingerprinting | 1 | 2021 | 181 | 0.180 |
Why?
|
| Gene Expression Profiling | 6 | 2020 | 5180 | 0.180 |
Why?
|
| RNA-Binding Proteins | 2 | 2018 | 1021 | 0.180 |
Why?
|
| Pyrimidines | 2 | 2011 | 3663 | 0.180 |
Why?
|
| Tissue Array Analysis | 2 | 2020 | 759 | 0.180 |
Why?
|
| RNA, Small Interfering | 8 | 2014 | 2218 | 0.180 |
Why?
|
| Osteonecrosis | 1 | 2020 | 56 | 0.180 |
Why?
|
| Databases, Nucleic Acid | 1 | 2020 | 116 | 0.180 |
Why?
|
| Pharmaceutical Preparations | 1 | 2021 | 157 | 0.170 |
Why?
|
| Lymphocyte Depletion | 1 | 2021 | 311 | 0.170 |
Why?
|
| Tumor Hypoxia | 1 | 2019 | 24 | 0.170 |
Why?
|
| Tertiary Lymphoid Structures | 1 | 2020 | 36 | 0.170 |
Why?
|
| Protein Interaction Maps | 1 | 2020 | 150 | 0.170 |
Why?
|
| Enzyme Inhibitors | 6 | 2014 | 1965 | 0.170 |
Why?
|
| Electron Transport Complex I | 1 | 2019 | 67 | 0.170 |
Why?
|
| Cell Division | 3 | 2002 | 2711 | 0.170 |
Why?
|
| Oxadiazoles | 1 | 2019 | 60 | 0.170 |
Why?
|
| Australia | 1 | 2020 | 261 | 0.170 |
Why?
|
| Receptors, OX40 | 1 | 2019 | 51 | 0.170 |
Why?
|
| Adenoviridae | 2 | 2002 | 1510 | 0.170 |
Why?
|
| Antibodies, Anti-Idiotypic | 1 | 2019 | 101 | 0.170 |
Why?
|
| Extracellular Signal-Regulated MAP Kinases | 2 | 2012 | 473 | 0.160 |
Why?
|
| Arabidopsis Proteins | 1 | 1999 | 52 | 0.160 |
Why?
|
| Colitis | 1 | 2022 | 344 | 0.160 |
Why?
|
| Probiotics | 1 | 2021 | 240 | 0.160 |
Why?
|
| Treatment Outcome | 14 | 2023 | 33846 | 0.160 |
Why?
|
| Myasthenia Gravis | 1 | 2019 | 108 | 0.160 |
Why?
|
| Plant Proteins | 1 | 1999 | 133 | 0.160 |
Why?
|
| DNA, Neoplasm | 3 | 2015 | 1972 | 0.160 |
Why?
|
| Interleukin-9 | 1 | 2018 | 37 | 0.160 |
Why?
|
| Skin Diseases | 1 | 2021 | 365 | 0.160 |
Why?
|
| Retrospective Studies | 13 | 2023 | 39731 | 0.160 |
Why?
|
| Enterocolitis | 1 | 2018 | 48 | 0.150 |
Why?
|
| Infliximab | 1 | 2018 | 139 | 0.150 |
Why?
|
| Neoplastic Cells, Circulating | 2 | 2020 | 640 | 0.150 |
Why?
|
| Potassium Channels | 1 | 1999 | 196 | 0.150 |
Why?
|
| Gene Expression Regulation, Enzymologic | 2 | 2012 | 704 | 0.150 |
Why?
|
| RNA | 1 | 2023 | 1069 | 0.150 |
Why?
|
| Erythema Nodosum | 1 | 2017 | 15 | 0.150 |
Why?
|
| Standard of Care | 2 | 2018 | 275 | 0.150 |
Why?
|
| Blotting, Western | 5 | 2013 | 3646 | 0.150 |
Why?
|
| Rare Diseases | 1 | 2021 | 360 | 0.150 |
Why?
|
| Gastrointestinal Agents | 1 | 2018 | 118 | 0.150 |
Why?
|
| Protective Factors | 1 | 2018 | 108 | 0.150 |
Why?
|
| HLA-A Antigens | 1 | 2018 | 105 | 0.150 |
Why?
|
| Base Sequence | 6 | 2021 | 5499 | 0.150 |
Why?
|
| Ribosomal Protein S6 Kinases, 70-kDa | 1 | 2018 | 135 | 0.150 |
Why?
|
| Panniculitis | 1 | 2017 | 58 | 0.140 |
Why?
|
| Adolescent | 8 | 2021 | 32609 | 0.140 |
Why?
|
| Up-Regulation | 3 | 2020 | 2457 | 0.140 |
Why?
|
| rac1 GTP-Binding Protein | 2 | 2014 | 110 | 0.140 |
Why?
|
| United States | 6 | 2021 | 16036 | 0.140 |
Why?
|
| Receptors, Androgen | 1 | 2022 | 909 | 0.140 |
Why?
|
| Pathology Department, Hospital | 1 | 2016 | 16 | 0.140 |
Why?
|
| RNA, Messenger | 4 | 2017 | 6488 | 0.140 |
Why?
|
| Interleukin-1beta | 2 | 2021 | 298 | 0.140 |
Why?
|
| Headache | 1 | 2017 | 174 | 0.130 |
Why?
|
| Neoplasm Recurrence, Local | 5 | 2022 | 10354 | 0.130 |
Why?
|
| Antigens, Differentiation, B-Lymphocyte | 1 | 2016 | 53 | 0.130 |
Why?
|
| Adenocarcinoma, Sebaceous | 1 | 2016 | 66 | 0.130 |
Why?
|
| Sebaceous Gland Neoplasms | 1 | 2016 | 100 | 0.130 |
Why?
|
| Tumor Suppressor Protein p53 | 6 | 2016 | 3670 | 0.130 |
Why?
|
| Clinical Trials, Phase III as Topic | 1 | 2017 | 484 | 0.130 |
Why?
|
| Meningeal Carcinomatosis | 1 | 2015 | 33 | 0.130 |
Why?
|
| Prostatic Neoplasms | 3 | 2002 | 5996 | 0.130 |
Why?
|
| Incidence | 3 | 2021 | 5856 | 0.130 |
Why?
|
| Neuregulin-1 | 1 | 2015 | 89 | 0.130 |
Why?
|
| CD8-Positive T-Lymphocytes | 3 | 2022 | 1657 | 0.130 |
Why?
|
| Drug Eruptions | 1 | 2017 | 271 | 0.130 |
Why?
|
| Histocompatibility Antigens Class II | 1 | 2016 | 191 | 0.120 |
Why?
|
| Anus Neoplasms | 1 | 2019 | 417 | 0.120 |
Why?
|
| Glycolysis | 1 | 2018 | 534 | 0.120 |
Why?
|
| Genetic Testing | 2 | 2015 | 1694 | 0.120 |
Why?
|
| Adrenal Cortex Hormones | 1 | 2018 | 566 | 0.120 |
Why?
|
| Receptor, ErbB-3 | 1 | 2015 | 126 | 0.120 |
Why?
|
| Oncogenes | 2 | 2016 | 701 | 0.120 |
Why?
|
| Microphthalmia-Associated Transcription Factor | 1 | 2014 | 42 | 0.120 |
Why?
|
| Dendritic Cells | 1 | 2021 | 1110 | 0.120 |
Why?
|
| Mechanistic Target of Rapamycin Complex 2 | 1 | 2014 | 69 | 0.120 |
Why?
|
| DNA Primers | 3 | 2013 | 1513 | 0.120 |
Why?
|
| Vulvar Neoplasms | 1 | 2016 | 236 | 0.120 |
Why?
|
| Quinolines | 2 | 2015 | 402 | 0.120 |
Why?
|
| Immunomodulation | 1 | 2016 | 253 | 0.120 |
Why?
|
| Stroke Volume | 1 | 2017 | 578 | 0.120 |
Why?
|
| Metalloproteins | 1 | 2014 | 26 | 0.120 |
Why?
|
| Pyridines | 2 | 2012 | 1311 | 0.120 |
Why?
|
| Multivariate Analysis | 2 | 2020 | 4352 | 0.120 |
Why?
|
| raf Kinases | 1 | 2014 | 80 | 0.120 |
Why?
|
| Fever | 1 | 2017 | 516 | 0.120 |
Why?
|
| Antigen Presentation | 1 | 2015 | 289 | 0.120 |
Why?
|
| 5' Untranslated Regions | 1 | 2014 | 99 | 0.110 |
Why?
|
| Drugs, Investigational | 1 | 2015 | 129 | 0.110 |
Why?
|
| MAP Kinase Kinase Kinase 5 | 1 | 2013 | 19 | 0.110 |
Why?
|
| Eye Neoplasms | 1 | 2016 | 257 | 0.110 |
Why?
|
| Histocompatibility Antigens Class I | 1 | 2015 | 247 | 0.110 |
Why?
|
| Phosphorylation | 7 | 2018 | 4984 | 0.110 |
Why?
|
| Smad4 Protein | 1 | 2015 | 202 | 0.110 |
Why?
|
| Proto-Oncogene Proteins | 3 | 2001 | 2624 | 0.110 |
Why?
|
| Ribosomal Proteins | 1 | 2014 | 135 | 0.110 |
Why?
|
| Exons | 3 | 2012 | 1388 | 0.110 |
Why?
|
| Gonanes | 1 | 2013 | 52 | 0.110 |
Why?
|
| B-Lymphocytes | 1 | 2020 | 1427 | 0.110 |
Why?
|
| Taxoids | 2 | 2016 | 1010 | 0.110 |
Why?
|
| C-Reactive Protein | 1 | 2017 | 567 | 0.110 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 2 | 2021 | 5566 | 0.110 |
Why?
|
| Genetic Loci | 1 | 2016 | 496 | 0.110 |
Why?
|
| Thioredoxins | 1 | 2013 | 51 | 0.110 |
Why?
|
| Niacinamide | 2 | 2012 | 427 | 0.110 |
Why?
|
| Mechanistic Target of Rapamycin Complex 1 | 1 | 2014 | 275 | 0.110 |
Why?
|
| Intestinal Mucosa | 1 | 2019 | 1125 | 0.110 |
Why?
|
| Quality Control | 1 | 2014 | 467 | 0.110 |
Why?
|
| Uveal Neoplasms | 2 | 2012 | 189 | 0.110 |
Why?
|
| Clonal Evolution | 1 | 2015 | 251 | 0.110 |
Why?
|
| Models, Genetic | 2 | 2014 | 1167 | 0.110 |
Why?
|
| Sequence Analysis, DNA | 3 | 2015 | 2574 | 0.110 |
Why?
|
| Oncogene Protein p21(ras) | 1 | 2012 | 48 | 0.100 |
Why?
|
| Mice, Nude | 5 | 2019 | 4358 | 0.100 |
Why?
|
| Antibodies | 1 | 2015 | 819 | 0.100 |
Why?
|
| Transcription Factors | 3 | 2017 | 5504 | 0.100 |
Why?
|
| Endoplasmic Reticulum Stress | 1 | 2014 | 195 | 0.100 |
Why?
|
| Chromosomal Proteins, Non-Histone | 1 | 2015 | 381 | 0.100 |
Why?
|
| GTP-Binding Protein alpha Subunits | 1 | 2012 | 41 | 0.100 |
Why?
|
| Lymphocyte Subsets | 1 | 2012 | 138 | 0.100 |
Why?
|
| Interleukin-1alpha | 1 | 2012 | 54 | 0.100 |
Why?
|
| Mice, Inbred C57BL | 6 | 2021 | 7222 | 0.100 |
Why?
|
| Disease Progression | 6 | 2023 | 6905 | 0.100 |
Why?
|
| Lymphangiogenesis | 1 | 2012 | 45 | 0.100 |
Why?
|
| Hamartoma Syndrome, Multiple | 1 | 2012 | 39 | 0.100 |
Why?
|
| Cluster Analysis | 2 | 2016 | 1074 | 0.100 |
Why?
|
| Biomarkers, Pharmacological | 1 | 2012 | 64 | 0.100 |
Why?
|
| Endothelial Cells | 2 | 2022 | 1047 | 0.100 |
Why?
|
| Patient Selection | 2 | 2019 | 2043 | 0.100 |
Why?
|
| Prospective Studies | 4 | 2023 | 13385 | 0.100 |
Why?
|
| Lysophospholipids | 1 | 2012 | 150 | 0.100 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 2 | 2013 | 1547 | 0.100 |
Why?
|
| Biomarkers | 3 | 2019 | 5111 | 0.100 |
Why?
|
| Glioblastoma | 2 | 2019 | 1781 | 0.100 |
Why?
|
| Tyrphostins | 1 | 2011 | 112 | 0.090 |
Why?
|
| Adenocarcinoma | 2 | 2016 | 7971 | 0.090 |
Why?
|
| Metalloproteases | 1 | 2010 | 20 | 0.090 |
Why?
|
| Benzenesulfonates | 1 | 2012 | 196 | 0.090 |
Why?
|
| Brain | 2 | 2014 | 4251 | 0.090 |
Why?
|
| Phosphotransferases | 1 | 2011 | 84 | 0.090 |
Why?
|
| Comparative Genomic Hybridization | 1 | 2013 | 691 | 0.090 |
Why?
|
| Hepatic Insufficiency | 1 | 2010 | 31 | 0.090 |
Why?
|
| Mutagenesis | 1 | 2012 | 524 | 0.090 |
Why?
|
| Genotype | 2 | 2017 | 4263 | 0.090 |
Why?
|
| Phosphatidic Acids | 1 | 2010 | 14 | 0.090 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 3 | 2014 | 3651 | 0.090 |
Why?
|
| Time Factors | 3 | 2021 | 13116 | 0.090 |
Why?
|
| T-Lymphocytes, Cytotoxic | 2 | 2012 | 1020 | 0.090 |
Why?
|
| Protein Binding | 5 | 2018 | 3526 | 0.090 |
Why?
|
| Extremities | 1 | 2012 | 308 | 0.090 |
Why?
|
| Phosphatidylinositol 3-Kinase | 1 | 2010 | 88 | 0.090 |
Why?
|
| Combined Modality Therapy | 5 | 2021 | 9042 | 0.090 |
Why?
|
| ADAM Proteins | 1 | 2010 | 114 | 0.090 |
Why?
|
| Ultraviolet Rays | 1 | 2012 | 591 | 0.090 |
Why?
|
| Blood-Brain Barrier | 1 | 2011 | 249 | 0.090 |
Why?
|
| Adaptor Proteins, Signal Transducing | 3 | 2016 | 1482 | 0.090 |
Why?
|
| Decision Support Techniques | 1 | 2015 | 604 | 0.090 |
Why?
|
| Gene Deletion | 2 | 2015 | 1486 | 0.090 |
Why?
|
| Interleukin-8 | 1 | 2012 | 531 | 0.090 |
Why?
|
| Muscle Proteins | 1 | 2013 | 560 | 0.080 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2018 | 2672 | 0.080 |
Why?
|
| Carcinogenesis | 1 | 2016 | 1037 | 0.080 |
Why?
|
| National Cancer Institute (U.S.) | 1 | 2010 | 218 | 0.080 |
Why?
|
| Dasatinib | 2 | 2011 | 881 | 0.080 |
Why?
|
| Lymph Nodes | 1 | 2020 | 3069 | 0.080 |
Why?
|
| Gene Frequency | 1 | 2011 | 1241 | 0.080 |
Why?
|
| Nuclear Proteins | 3 | 2017 | 3472 | 0.080 |
Why?
|
| Proto-Oncogene Proteins c-met | 1 | 2012 | 428 | 0.080 |
Why?
|
| Biopsy | 4 | 2019 | 3544 | 0.080 |
Why?
|
| Kaplan-Meier Estimate | 4 | 2021 | 6266 | 0.080 |
Why?
|
| Receptors, N-Methyl-D-Aspartate | 1 | 2011 | 269 | 0.080 |
Why?
|
| Nevus, Pigmented | 1 | 2009 | 116 | 0.080 |
Why?
|
| Models, Molecular | 2 | 2012 | 1755 | 0.080 |
Why?
|
| Neoplasm Transplantation | 2 | 2021 | 1566 | 0.080 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 2 | 2012 | 1408 | 0.080 |
Why?
|
| src-Family Kinases | 1 | 2011 | 487 | 0.080 |
Why?
|
| Receptors, G-Protein-Coupled | 1 | 2011 | 487 | 0.080 |
Why?
|
| Xenograft Model Antitumor Assays | 5 | 2019 | 3924 | 0.080 |
Why?
|
| Confidence Intervals | 2 | 2021 | 758 | 0.080 |
Why?
|
| Antibodies, Monoclonal, Humanized | 4 | 2021 | 3391 | 0.070 |
Why?
|
| Lysine | 1 | 2010 | 428 | 0.070 |
Why?
|
| Gene Amplification | 1 | 2011 | 770 | 0.070 |
Why?
|
| Gene Expression | 4 | 2018 | 3688 | 0.070 |
Why?
|
| Autophagy | 1 | 2014 | 921 | 0.070 |
Why?
|
| Carcinoma | 1 | 1999 | 2623 | 0.070 |
Why?
|
| Sentinel Lymph Node Biopsy | 3 | 2022 | 1450 | 0.070 |
Why?
|
| Software | 1 | 2014 | 1383 | 0.070 |
Why?
|
| Sirolimus | 1 | 2012 | 833 | 0.070 |
Why?
|
| Carcinoma, Renal Cell | 1 | 2020 | 2417 | 0.070 |
Why?
|
| Precision Medicine | 1 | 2015 | 1206 | 0.070 |
Why?
|
| Clone Cells | 2 | 2020 | 589 | 0.070 |
Why?
|
| Algorithms | 2 | 2016 | 3922 | 0.070 |
Why?
|
| Cisplatin | 2 | 2014 | 2497 | 0.070 |
Why?
|
| Head and Neck Neoplasms | 2 | 2012 | 4136 | 0.070 |
Why?
|
| Genome-Wide Association Study | 2 | 2012 | 2331 | 0.070 |
Why?
|
| Vincristine | 1 | 2010 | 1572 | 0.070 |
Why?
|
| ErbB Receptors | 3 | 2021 | 2383 | 0.070 |
Why?
|
| Maximum Tolerated Dose | 3 | 2015 | 1323 | 0.070 |
Why?
|
| Antineoplastic Agents, Phytogenic | 1 | 2010 | 895 | 0.070 |
Why?
|
| Disease Models, Animal | 5 | 2020 | 7463 | 0.060 |
Why?
|
| MAP Kinase Kinase Kinases | 2 | 2019 | 188 | 0.060 |
Why?
|
| B7-H1 Antigen | 3 | 2017 | 1072 | 0.060 |
Why?
|
| DNA-Binding Proteins | 2 | 2017 | 5067 | 0.060 |
Why?
|
| Molecular Sequence Data | 4 | 2014 | 6781 | 0.060 |
Why?
|
| Receptor, ErbB-2 | 1 | 2015 | 2649 | 0.060 |
Why?
|
| Imatinib Mesylate | 1 | 2009 | 1690 | 0.060 |
Why?
|
| Genome, Human | 1 | 2013 | 1878 | 0.060 |
Why?
|
| STAT3 Transcription Factor | 1 | 2011 | 1146 | 0.060 |
Why?
|
| Exome | 3 | 2016 | 1250 | 0.060 |
Why?
|
| Polymorphism, Single Nucleotide | 3 | 2015 | 4636 | 0.060 |
Why?
|
| Colonic Neoplasms | 1 | 2012 | 1443 | 0.060 |
Why?
|
| Enzyme Activation | 3 | 2009 | 1832 | 0.060 |
Why?
|
| Cyclophosphamide | 1 | 2011 | 3231 | 0.060 |
Why?
|
| Predictive Value of Tests | 3 | 2019 | 4998 | 0.060 |
Why?
|
| Lymph Node Excision | 2 | 2022 | 2045 | 0.060 |
Why?
|
| Gene Dosage | 2 | 2017 | 829 | 0.050 |
Why?
|
| Cells, Cultured | 4 | 2012 | 5779 | 0.050 |
Why?
|
| Dacarbazine | 2 | 2016 | 505 | 0.050 |
Why?
|
| Phosphoproteins | 1 | 2009 | 1230 | 0.050 |
Why?
|
| Survival Rate | 3 | 2022 | 12530 | 0.050 |
Why?
|
| Prevalence | 1 | 2011 | 3423 | 0.050 |
Why?
|
| Computational Biology | 2 | 2020 | 1278 | 0.050 |
Why?
|
| Bromodeoxyuridine | 1 | 2002 | 138 | 0.050 |
Why?
|
| Mice, SCID | 2 | 2021 | 1851 | 0.050 |
Why?
|
| Phosphotyrosine | 1 | 2002 | 125 | 0.050 |
Why?
|
| Cell Cycle | 2 | 2012 | 2150 | 0.050 |
Why?
|
| Gene Expression Regulation | 1 | 2013 | 4193 | 0.050 |
Why?
|
| Polymerase Chain Reaction | 1 | 2008 | 3512 | 0.050 |
Why?
|
| Fatty Acids, Volatile | 1 | 2021 | 52 | 0.050 |
Why?
|
| In Situ Nick-End Labeling | 1 | 2002 | 449 | 0.050 |
Why?
|
| Proportional Hazards Models | 2 | 2023 | 5113 | 0.050 |
Why?
|
| Melanocytes | 2 | 2012 | 241 | 0.050 |
Why?
|
| MART-1 Antigen | 1 | 2021 | 113 | 0.050 |
Why?
|
| Receptors, Lysophosphatidic Acid | 2 | 2012 | 89 | 0.050 |
Why?
|
| Morpholines | 2 | 2015 | 296 | 0.050 |
Why?
|
| Anal Canal | 1 | 2022 | 238 | 0.050 |
Why?
|
| Genetic Vectors | 2 | 2013 | 1883 | 0.050 |
Why?
|
| Fecal Microbiota Transplantation | 1 | 2021 | 161 | 0.050 |
Why?
|
| Response Evaluation Criteria in Solid Tumors | 1 | 2021 | 164 | 0.050 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2017 | 7929 | 0.050 |
Why?
|
| Myeloid Cells | 1 | 2022 | 277 | 0.050 |
Why?
|
| Dose-Response Relationship, Drug | 3 | 2014 | 5102 | 0.050 |
Why?
|
| Piperazines | 1 | 2009 | 2151 | 0.040 |
Why?
|
| Neutrophil Activation | 1 | 2020 | 35 | 0.040 |
Why?
|
| Organ Sparing Treatments | 1 | 2022 | 280 | 0.040 |
Why?
|
| Dendritic Cells, Follicular | 1 | 2020 | 40 | 0.040 |
Why?
|
| Superoxide Dismutase | 1 | 2021 | 269 | 0.040 |
Why?
|
| Cell Movement | 3 | 2012 | 2503 | 0.040 |
Why?
|
| Drug Synergism | 2 | 2015 | 1364 | 0.040 |
Why?
|
| Carbamates | 1 | 2019 | 81 | 0.040 |
Why?
|
| Cytokines | 2 | 2015 | 2837 | 0.040 |
Why?
|
| Cell- and Tissue-Based Therapy | 1 | 2022 | 382 | 0.040 |
Why?
|
| Inhibitory Concentration 50 | 1 | 2019 | 286 | 0.040 |
Why?
|
| Metabolic Flux Analysis | 1 | 2019 | 27 | 0.040 |
Why?
|
| Overweight | 1 | 2023 | 487 | 0.040 |
Why?
|
| Cell Membrane | 2 | 2015 | 900 | 0.040 |
Why?
|
| HEK293 Cells | 2 | 2013 | 1468 | 0.040 |
Why?
|
| Nitroimidazoles | 1 | 2019 | 107 | 0.040 |
Why?
|
| User-Computer Interface | 1 | 2020 | 304 | 0.040 |
Why?
|
| Tumor Burden | 2 | 2016 | 2035 | 0.040 |
Why?
|
| Phenotype | 2 | 2020 | 6510 | 0.040 |
Why?
|
| Antigens, Differentiation | 1 | 2019 | 253 | 0.040 |
Why?
|
| Cell Cycle Checkpoints | 1 | 2020 | 272 | 0.040 |
Why?
|
| Fluorescent Antibody Technique | 1 | 2021 | 1142 | 0.040 |
Why?
|
| Immunologic Factors | 1 | 2022 | 668 | 0.040 |
Why?
|
| Interferon Regulatory Factor-1 | 1 | 2018 | 54 | 0.040 |
Why?
|
| Receptors, Immunologic | 1 | 2020 | 318 | 0.040 |
Why?
|
| Chemokine CXCL10 | 1 | 2018 | 106 | 0.040 |
Why?
|
| Suppression, Genetic | 1 | 2017 | 71 | 0.040 |
Why?
|
| Feces | 1 | 2021 | 865 | 0.040 |
Why?
|
| Immunologic Memory | 1 | 2020 | 380 | 0.040 |
Why?
|
| Symptom Assessment | 1 | 2019 | 274 | 0.040 |
Why?
|
| Interleukin-6 | 1 | 2022 | 1066 | 0.040 |
Why?
|
| Cell-Free Nucleic Acids | 1 | 2020 | 232 | 0.040 |
Why?
|
| Immunoenzyme Techniques | 2 | 2010 | 1209 | 0.040 |
Why?
|
| Mass Spectrometry | 1 | 2020 | 726 | 0.040 |
Why?
|
| Cyclin-Dependent Kinase 6 | 1 | 2018 | 137 | 0.040 |
Why?
|
| Heterografts | 1 | 2019 | 745 | 0.040 |
Why?
|
| Drug Therapy, Combination | 1 | 2022 | 2365 | 0.040 |
Why?
|
| Mohs Surgery | 1 | 2018 | 102 | 0.040 |
Why?
|
| Cyclin-Dependent Kinase 4 | 1 | 2018 | 212 | 0.030 |
Why?
|
| Ribosomal Protein S6 | 1 | 2016 | 48 | 0.030 |
Why?
|
| 3' Untranslated Regions | 1 | 2018 | 339 | 0.030 |
Why?
|
| Transgenes | 1 | 1998 | 589 | 0.030 |
Why?
|
| Follow-Up Studies | 3 | 2019 | 15254 | 0.030 |
Why?
|
| Retinoblastoma Binding Proteins | 1 | 2016 | 66 | 0.030 |
Why?
|
| Mitotic Index | 1 | 2016 | 166 | 0.030 |
Why?
|
| Metabolome | 1 | 2019 | 356 | 0.030 |
Why?
|
| Macrophages | 1 | 2022 | 1376 | 0.030 |
Why?
|
| CD8 Antigens | 1 | 2016 | 173 | 0.030 |
Why?
|
| Macrophage Migration-Inhibitory Factors | 1 | 2016 | 37 | 0.030 |
Why?
|
| Cytotoxicity, Immunologic | 1 | 2018 | 683 | 0.030 |
Why?
|
| Genes, Reporter | 1 | 2018 | 832 | 0.030 |
Why?
|
| Single-Cell Analysis | 1 | 2020 | 540 | 0.030 |
Why?
|
| Mitogen-Activated Protein Kinase 3 | 1 | 2016 | 278 | 0.030 |
Why?
|
| Pancreatic Neoplasms | 1 | 2013 | 5246 | 0.030 |
Why?
|
| Intramolecular Oxidoreductases | 1 | 2016 | 88 | 0.030 |
Why?
|
| Amino Acid Sequence | 2 | 2012 | 4635 | 0.030 |
Why?
|
| Sequence Analysis, RNA | 1 | 2019 | 679 | 0.030 |
Why?
|
| Oxygen | 1 | 2019 | 800 | 0.030 |
Why?
|
| Mitogen-Activated Protein Kinase 1 | 1 | 2016 | 298 | 0.030 |
Why?
|
| Injections, Spinal | 1 | 2015 | 275 | 0.030 |
Why?
|
| SMARCB1 Protein | 1 | 2015 | 109 | 0.030 |
Why?
|
| Nitrosation | 1 | 2014 | 9 | 0.030 |
Why?
|
| Genetic Therapy | 1 | 2002 | 1732 | 0.030 |
Why?
|
| Academic Medical Centers | 1 | 2018 | 690 | 0.030 |
Why?
|
| Mutagenesis, Insertional | 1 | 2015 | 219 | 0.030 |
Why?
|
| Microsatellite Instability | 1 | 2016 | 410 | 0.030 |
Why?
|
| Freezing | 1 | 2014 | 61 | 0.030 |
Why?
|
| Radiopharmaceuticals | 1 | 2019 | 1338 | 0.030 |
Why?
|
| Drug Approval | 1 | 2015 | 176 | 0.030 |
Why?
|
| Aminopyridines | 1 | 2015 | 223 | 0.030 |
Why?
|
| Protein Interaction Domains and Motifs | 1 | 2015 | 273 | 0.030 |
Why?
|
| Chick Embryo | 1 | 2014 | 219 | 0.030 |
Why?
|
| Case-Control Studies | 1 | 2023 | 6230 | 0.030 |
Why?
|
| Interferon-gamma | 1 | 2018 | 1180 | 0.030 |
Why?
|
| Gene Fusion | 1 | 2015 | 214 | 0.030 |
Why?
|
| Down-Regulation | 2 | 2015 | 2105 | 0.030 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 1 | 2018 | 629 | 0.030 |
Why?
|
| Positron Emission Tomography Computed Tomography | 1 | 2019 | 879 | 0.030 |
Why?
|
| United States Food and Drug Administration | 1 | 2015 | 329 | 0.030 |
Why?
|
| Protein-Tyrosine Kinases | 1 | 2001 | 1842 | 0.030 |
Why?
|
| Frozen Sections | 1 | 2014 | 118 | 0.030 |
Why?
|
| Liver Neoplasms | 1 | 2010 | 4805 | 0.030 |
Why?
|
| Paraffin Embedding | 1 | 2014 | 229 | 0.030 |
Why?
|
| MAP Kinase Kinase 4 | 1 | 2013 | 143 | 0.030 |
Why?
|
| Antineoplastic Agents, Alkylating | 1 | 2016 | 609 | 0.030 |
Why?
|
| Fatal Outcome | 1 | 2015 | 835 | 0.030 |
Why?
|
| Genome | 1 | 2017 | 690 | 0.030 |
Why?
|
| T-Lymphocyte Subsets | 1 | 2016 | 595 | 0.030 |
Why?
|
| Cancer Care Facilities | 1 | 2018 | 908 | 0.030 |
Why?
|
| Lentivirus | 1 | 2013 | 166 | 0.030 |
Why?
|
| Protein Multimerization | 1 | 2014 | 233 | 0.030 |
Why?
|
| Protein Transport | 1 | 2015 | 739 | 0.030 |
Why?
|
| GTP-Binding Protein alpha Subunits, Gq-G11 | 1 | 2012 | 51 | 0.030 |
Why?
|
| Databases, Genetic | 1 | 2016 | 751 | 0.030 |
Why?
|
| ROC Curve | 1 | 2016 | 1248 | 0.030 |
Why?
|
| Duodenal Neoplasms | 1 | 2013 | 139 | 0.030 |
Why?
|
| Common Bile Duct Neoplasms | 1 | 2013 | 150 | 0.030 |
Why?
|
| Immunoprecipitation | 1 | 2013 | 593 | 0.030 |
Why?
|
| Mutation Rate | 1 | 2012 | 220 | 0.020 |
Why?
|
| Administration, Metronomic | 1 | 2011 | 15 | 0.020 |
Why?
|
| Hepatocyte Growth Factor | 1 | 2012 | 154 | 0.020 |
Why?
|
| Administration, Oral | 1 | 2015 | 1618 | 0.020 |
Why?
|
| Epithelial-Mesenchymal Transition | 1 | 2017 | 1004 | 0.020 |
Why?
|
| Methylation | 1 | 2012 | 626 | 0.020 |
Why?
|
| Pharmaceutical Vehicles | 1 | 2010 | 14 | 0.020 |
Why?
|
| ADAMTS Proteins | 1 | 2010 | 14 | 0.020 |
Why?
|
| Sulfones | 1 | 2012 | 149 | 0.020 |
Why?
|
| Cyclin D1 | 1 | 2013 | 591 | 0.020 |
Why?
|
| Transcriptome | 1 | 2020 | 1940 | 0.020 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p16 | 1 | 2013 | 507 | 0.020 |
Why?
|
| Lymphatic Vessels | 1 | 2012 | 140 | 0.020 |
Why?
|
| Gene Knockdown Techniques | 1 | 2014 | 1085 | 0.020 |
Why?
|
| Tubulin Modulators | 1 | 2010 | 65 | 0.020 |
Why?
|
| Phosphodiesterase I | 1 | 2010 | 19 | 0.020 |
Why?
|
| Metabolic Clearance Rate | 1 | 2010 | 241 | 0.020 |
Why?
|
| Half-Life | 1 | 2010 | 269 | 0.020 |
Why?
|
| Tissue Distribution | 1 | 2012 | 946 | 0.020 |
Why?
|
| Sequence Alignment | 1 | 2012 | 883 | 0.020 |
Why?
|
| Immunophenotyping | 1 | 2015 | 1729 | 0.020 |
Why?
|
| Pyrophosphatases | 1 | 2010 | 49 | 0.020 |
Why?
|
| Cell Growth Processes | 1 | 2010 | 339 | 0.020 |
Why?
|
| Phosphoric Diester Hydrolases | 1 | 2010 | 112 | 0.020 |
Why?
|
| Interferon-alpha | 1 | 2014 | 961 | 0.020 |
Why?
|
| Nitric Oxide | 1 | 2014 | 665 | 0.020 |
Why?
|
| Genes, p53 | 1 | 2014 | 1146 | 0.020 |
Why?
|
| Evidence-Based Medicine | 1 | 2015 | 1059 | 0.020 |
Why?
|
| Cell Death | 1 | 2012 | 689 | 0.020 |
Why?
|
| Threonine | 1 | 2010 | 165 | 0.020 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2018 | 3976 | 0.020 |
Why?
|
| Protein Processing, Post-Translational | 1 | 2014 | 815 | 0.020 |
Why?
|
| Ascites | 1 | 2010 | 216 | 0.020 |
Why?
|
| Germ-Line Mutation | 1 | 2015 | 1101 | 0.020 |
Why?
|
| Real-Time Polymerase Chain Reaction | 1 | 2013 | 1212 | 0.020 |
Why?
|
| Feasibility Studies | 1 | 2015 | 2348 | 0.020 |
Why?
|
| Gene Silencing | 1 | 2012 | 832 | 0.020 |
Why?
|
| Sequence Homology, Amino Acid | 1 | 2011 | 1093 | 0.020 |
Why?
|
| Chromones | 1 | 2009 | 121 | 0.020 |
Why?
|
| Models, Biological | 1 | 2018 | 3223 | 0.020 |
Why?
|
| Multienzyme Complexes | 1 | 2010 | 227 | 0.020 |
Why?
|
| Genes, Neoplasm | 1 | 2010 | 317 | 0.020 |
Why?
|
| Telomere | 1 | 2012 | 545 | 0.020 |
Why?
|
| Melphalan | 1 | 2012 | 875 | 0.020 |
Why?
|
| Pyridazines | 1 | 2012 | 319 | 0.020 |
Why?
|
| Glutamic Acid | 1 | 2011 | 335 | 0.020 |
Why?
|
| Positron-Emission Tomography | 1 | 2018 | 2198 | 0.020 |
Why?
|
| Stromal Cells | 1 | 2012 | 835 | 0.020 |
Why?
|
| Liposomes | 1 | 2010 | 710 | 0.020 |
Why?
|
| Mutation, Missense | 1 | 2014 | 1198 | 0.020 |
Why?
|
| Angiogenesis Inhibitors | 1 | 2015 | 1264 | 0.020 |
Why?
|
| Green Fluorescent Proteins | 1 | 2010 | 702 | 0.020 |
Why?
|
| Cell Adhesion | 1 | 2010 | 1041 | 0.020 |
Why?
|
| Fluorescent Dyes | 1 | 2010 | 468 | 0.020 |
Why?
|
| Proto-Oncogene Proteins c-myc | 1 | 2012 | 845 | 0.020 |
Why?
|
| Mice, Inbred NOD | 1 | 2010 | 910 | 0.020 |
Why?
|
| Epigenesis, Genetic | 1 | 2015 | 1438 | 0.020 |
Why?
|
| Immunoblotting | 1 | 2009 | 910 | 0.020 |
Why?
|
| Transplantation, Autologous | 1 | 2012 | 2049 | 0.020 |
Why?
|
| RNA Interference | 1 | 2012 | 1397 | 0.020 |
Why?
|
| T-Lymphocytes, Regulatory | 1 | 2011 | 716 | 0.020 |
Why?
|
| Texas | 1 | 2018 | 6434 | 0.020 |
Why?
|
| HeLa Cells | 1 | 2010 | 1717 | 0.020 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 2012 | 1588 | 0.020 |
Why?
|
| Remission Induction | 1 | 2012 | 3645 | 0.020 |
Why?
|
| Sensitivity and Specificity | 1 | 2015 | 5195 | 0.020 |
Why?
|
| Azacitidine | 1 | 2012 | 1218 | 0.020 |
Why?
|
| Antigens, Neoplasm | 1 | 2012 | 1589 | 0.020 |
Why?
|
| Endothelium, Vascular | 1 | 2010 | 896 | 0.020 |
Why?
|
| Promoter Regions, Genetic | 1 | 2012 | 3262 | 0.020 |
Why?
|
| NF-kappa B | 1 | 2012 | 1568 | 0.020 |
Why?
|
| Breast Neoplasms | 1 | 2009 | 16226 | 0.020 |
Why?
|
| Reproducibility of Results | 1 | 2015 | 6208 | 0.020 |
Why?
|
| Sequence Analysis, Protein | 1 | 2002 | 80 | 0.010 |
Why?
|
| Amino Acid Motifs | 1 | 2002 | 415 | 0.010 |
Why?
|
| Catalytic Domain | 1 | 2002 | 306 | 0.010 |
Why?
|
| Androstadienes | 1 | 2001 | 171 | 0.010 |
Why?
|
| Cell Cycle Proteins | 1 | 2009 | 2128 | 0.010 |
Why?
|
| MicroRNAs | 1 | 2013 | 2912 | 0.010 |
Why?
|
| Kinetics | 1 | 2002 | 2242 | 0.010 |
Why?
|
| bcl-X Protein | 1 | 1999 | 199 | 0.010 |
Why?
|
| Protein Structure, Tertiary | 1 | 2002 | 1500 | 0.010 |
Why?
|
| Epidermis | 1 | 1999 | 200 | 0.010 |
Why?
|
| bcl-2-Associated X Protein | 1 | 1999 | 380 | 0.010 |
Why?
|
| Keratinocytes | 1 | 1999 | 247 | 0.010 |
Why?
|
| Binding Sites | 1 | 2002 | 2298 | 0.010 |
Why?
|
| Carcinoma, Basal Cell | 1 | 1999 | 290 | 0.010 |
Why?
|
| Child | 1 | 2016 | 30401 | 0.010 |
Why?
|
| Glioma | 1 | 2002 | 1988 | 0.010 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 1999 | 5601 | 0.000 |
Why?
|